Observational study reveals variability in treatment outcomes for infants with ROP receiving ranibizumab and PRP.
Ranibizumab was initiated at a younger age with higher retreatment and reactivation events compared to PRP, underscoring variability in real-world ROP treatment patterns and outcomes.
No takes yet. Share an insight, caveat, or question.
Vought et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: